Atlas Trials

Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG

Clinical trial NCT07644312 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07644312
Sponsor
Nationwide Children's Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
High Grade GliomaDiffuse Intrinsic Pontine GliomaWHO Grade 3 GliomaWHO Grade 4 GliomaReplication Repair Deficient
Start date
2027-03-01
Primary completion
2033-03-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.